MedTrace Logo

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

NCT01090622 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2012-03-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether XPF-001 is safe and effective in the treatment of pain caused by Inherited Erythromelalgia (IEM).

Conditions

  • Primary Erythromelalgia
  • Inherited Erythromelalgia

Interventions

DRUG

XPF-001

Oral capsule

DRUG

Placebo

Oral capsule

Sponsors & Collaborators

Principal Investigators

  • Joost PH Drenth, MD PhD · Radboud University Nijmegen Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-08-31
Completion
2010-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01090622 on ClinicalTrials.gov